Discover the latest on Rhythm Pharmaceuticals, Inc. and its asset, imcivree, targeting rare obesity disorders and potential ...
SOUTH SAN FRANCISCO, CA, USA I 05, 2024 I Denali Therapeutics Inc. (Nasdaq: DNLI) today announced initiation of dosing in a global Phase 2a clinical ...
This study provides valuable evidence for the mechanism underlying KCNC1-related developmental and epileptic encephalopathy. The authors have generated and characterized a new knock-in mouse with a ...
Innovent Biologics, Inc. ('Innovent') (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and ...
The therapy failed to slow disease progression in patients with early Alzheimer’s in the INVOKE-2 trial (NCT04592874).
Zinc supplementation was started. Genetic testing done simultaneously showed compound heterozygous mutations in SLC39A4 in ...